SAN
DIEGO, Feb. 25, 2025 /PRNewswire/ -- Avidity
Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company
committed to delivering a new class of RNA therapeutics called
Antibody Oligonucleotide Conjugates (AOCs™), today announced that
Avidity management will participate in a fireside chat during each
of the following investor conferences:
- TD Cowen 45th Annual Health Care Conference on
Tuesday, March 4, 2025, at
3:10 p.m. ET
- Leerink Partners Global Healthcare Conference on
Tuesday, March 11, 2025, at
1:00 p.m. ET
- Barclays 27th Annual Global Healthcare Conference on
Wednesday, March 12, 2025, at
11:30 a.m. ET
Live webcasts of each event, up-to-date event details and
archived replays will be available on the "Events and
Presentations" page in the "Investors" section of Avidity's website
at
https://aviditybiosciences.investorroom.com/events-and-presentations.
About Avidity
Avidity Biosciences, Inc.'s mission is
to profoundly improve people's lives by delivering a new class of
RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™).
Avidity is revolutionizing the field of RNA with its proprietary
AOCs, which are designed to combine the specificity of monoclonal
antibodies with the precision of oligonucleotide therapies to
address targets and diseases previously unreachable with existing
RNA therapies. Utilizing its proprietary AOC platform, Avidity
demonstrated the first-ever successful targeted delivery of RNA
into muscle and is leading the field with clinical development
programs for three rare neuromuscular diseases: myotonic dystrophy
type 1 (DM1), Duchenne muscular dystrophy (DMD) and
facioscapulohumeral muscular dystrophy (FSHD). Avidity is also
advancing two wholly-owned precision cardiology development
candidates addressing rare genetic cardiomyopathies. In addition,
Avidity is broadening the reach of AOCs with its advancing and
expanding pipeline including programs in cardiology and
immunology through key partnerships. Avidity is headquartered
in San Diego, CA. For more
information about our AOC platform, clinical development pipeline
and people, please visit www.aviditybiosciences.com and engage
with us on LinkedIn and X.
Investor Contact:
Kat Lange
(619) 837-5014
investors@aviditybio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conferences-302382513.html
SOURCE Avidity Biosciences, Inc.